Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Exploring novel genomic biomarkers for response and survival after neoadjuvant chemotherapy and radical cystectomy of muscle-invasive bladder cancer

Holmsten, K. ; De Laere, B. ; Sjödahl, G. LU orcid ; Lindberg, J. ; Costa Svedman, F. ; Östling, P. ; Eriksson, P. LU ; Liedberg, F. LU and Ullén, A. (2025) In ESMO Open 10(8).
Abstract

Background: Neoadjuvant cisplatin-based combination chemotherapy (NAC) is standard perioperative treatment of patients with muscle-invasive urothelial bladder cancer (MIBC); however, about half of the patients experience recurrence of the disease. Biomarkers for response and survival represent an unmet medical need. We used tumor specimens from transurethral resections of the bladder to explore genomic alterations and their association with response and survival in MIBC patients treated by NAC and radical cystectomy. Patients and methods: A pan cancer panel with single-nucleotide polymorphism backbone-based sequencing approach with coverage of the most commonly perturbed cancer genes and low-pass whole genome sequencing was applied for... (More)

Background: Neoadjuvant cisplatin-based combination chemotherapy (NAC) is standard perioperative treatment of patients with muscle-invasive urothelial bladder cancer (MIBC); however, about half of the patients experience recurrence of the disease. Biomarkers for response and survival represent an unmet medical need. We used tumor specimens from transurethral resections of the bladder to explore genomic alterations and their association with response and survival in MIBC patients treated by NAC and radical cystectomy. Patients and methods: A pan cancer panel with single-nucleotide polymorphism backbone-based sequencing approach with coverage of the most commonly perturbed cancer genes and low-pass whole genome sequencing was applied for genomic characterization of 110 clinical routine patients treated with NAC before radical cystectomy. Pathological response rates, recurrence-free and overall survival were assessed. Results: Amplifications of genes on chromosome 6p22.3, particularly of the E2F3 and SOX4 gene loci, were associated with improved response and survival to NAC. Patients harboring these alterations had a high pathological treatment response rate and all remained recurrence-free during a median follow-up of 5 years. Conversely, patients with FGFR3 mutations demonstrated impaired response and survival, whereas CDKN1A mutations appeared not related to treatment response but may serve as a biomarker for poor prognosis. Conclusions: We found the panel-based sequencing approach feasible for exploring genomic alterations associated with clinical benefits of NAC and radical cystectomy. Amplifications of genes on chromosome 6p22.3 and FGFR3 and CDKN1A mutations hold promise as biomarkers associated with response and survival to NAC.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
amplification of chromosome 6p22.3, FGFR3 mutations, genomic biomarkers, muscle-invasive bladder cancer, neoadjuvant chemotherapy, pan cancer panel DNA sequencing
in
ESMO Open
volume
10
issue
8
article number
105512
publisher
BMJ Publishing Group
external identifiers
  • pmid:40664147
  • scopus:105010472724
ISSN
2059-7029
DOI
10.1016/j.esmoop.2025.105512
language
English
LU publication?
yes
additional info
Publisher Copyright: © 2025 The Author(s)
id
415f1123-546f-4b4a-891d-2275a61a8951
date added to LUP
2025-12-12 14:46:28
date last changed
2025-12-12 14:47:31
@article{415f1123-546f-4b4a-891d-2275a61a8951,
  abstract     = {{<p>Background: Neoadjuvant cisplatin-based combination chemotherapy (NAC) is standard perioperative treatment of patients with muscle-invasive urothelial bladder cancer (MIBC); however, about half of the patients experience recurrence of the disease. Biomarkers for response and survival represent an unmet medical need. We used tumor specimens from transurethral resections of the bladder to explore genomic alterations and their association with response and survival in MIBC patients treated by NAC and radical cystectomy. Patients and methods: A pan cancer panel with single-nucleotide polymorphism backbone-based sequencing approach with coverage of the most commonly perturbed cancer genes and low-pass whole genome sequencing was applied for genomic characterization of 110 clinical routine patients treated with NAC before radical cystectomy. Pathological response rates, recurrence-free and overall survival were assessed. Results: Amplifications of genes on chromosome 6p22.3, particularly of the E2F3 and SOX4 gene loci, were associated with improved response and survival to NAC. Patients harboring these alterations had a high pathological treatment response rate and all remained recurrence-free during a median follow-up of 5 years. Conversely, patients with FGFR3 mutations demonstrated impaired response and survival, whereas CDKN1A mutations appeared not related to treatment response but may serve as a biomarker for poor prognosis. Conclusions: We found the panel-based sequencing approach feasible for exploring genomic alterations associated with clinical benefits of NAC and radical cystectomy. Amplifications of genes on chromosome 6p22.3 and FGFR3 and CDKN1A mutations hold promise as biomarkers associated with response and survival to NAC.</p>}},
  author       = {{Holmsten, K. and De Laere, B. and Sjödahl, G. and Lindberg, J. and Costa Svedman, F. and Östling, P. and Eriksson, P. and Liedberg, F. and Ullén, A.}},
  issn         = {{2059-7029}},
  keywords     = {{amplification of chromosome 6p22.3; FGFR3 mutations; genomic biomarkers; muscle-invasive bladder cancer; neoadjuvant chemotherapy; pan cancer panel DNA sequencing}},
  language     = {{eng}},
  number       = {{8}},
  publisher    = {{BMJ Publishing Group}},
  series       = {{ESMO Open}},
  title        = {{Exploring novel genomic biomarkers for response and survival after neoadjuvant chemotherapy and radical cystectomy of muscle-invasive bladder cancer}},
  url          = {{http://dx.doi.org/10.1016/j.esmoop.2025.105512}},
  doi          = {{10.1016/j.esmoop.2025.105512}},
  volume       = {{10}},
  year         = {{2025}},
}